No profile data available.
Foghorn Therapeutics Inc. (FHTX) is a healthcare company in the additional cancer treatment drugs industry, based in Watertown, United States, with about 106 full-time employees.
It reported revenue of $30.91 million for fiscal year 2025, up 36.8% from fiscal year 2024, and net income of -$74.28 million. Its market capitalization was $118.77 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Foghorn Therapeutics reported $30.91 million in revenue for fiscal year 2025, up 36.8% from $22.60 million in fiscal year 2024.
$118.77 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Kazia Therapeutics Limited (KZIA), TuHURA Biosciences, Inc. (HURA), Inovio Pharmaceuticals, Inc. (INO), enGene Holdings Inc. (ENGN).